The global breast cancer screening tests market was valued at USD 1.9 Billion in 2022 and is expected to reach USD 4.4 Billion by 2033. The imaging tests segment with around 54.3% value share, has topped the global market within the product category in 2022 and is expected to grow at a CAGR of close to 7.8% over the forecast period (2023 to 2033)
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 1.9 Billion |
| Market Value 2023 | USD 2.1 Billion |
| Market Value 2033 | USD 4.4 Billion |
| CAGR 2023 to 2033 | 7.8% |
| Market Share of Top 5 Countries | 54.5% |
| Key Market Players | AstraZeneca; Novartis; Sanofi; Pfizer; Bayer AG; GlaxoSmithKline plc; and Siemens Healthineers; Hologic Inc. |
Diagnostic tests are critical in giving accurate care to patients. More precise breast imaging technologies have been developed over the last decades, which has helped to minimise the disease burden of breast cancer.
Since breast cancer is one of the most common cancers in women, the development of various breast cancer awareness programmes has been critical, and many agencies, including the FDA, have launched breast cancer awareness programmes such as the Pink Ribbon Sunday Mammography Awareness Program.
The global market for breast cancer screening tests was around 1.0% of the overall USD 191.0 Billion of the global cancer diagnostics market in 2022.
Growing demand for technologically sophisticated testing kits and instruments that may improve accuracy, speed, and cost-effectiveness for diagnosis is expected to be the most important growth factor over the projection period.
Rising reimbursement and insurance coverage are likely to further boost testing adoption. Government bodies across various countries have approved certain tests for nationwide reimbursement. This has led to an increase in number of tests being performed either at point-of-care testing site or at the convenience of home.
Patient advocacy organisations and organisations dedicated to breast cancer awareness and assistance are critical in boosting demand for screening tests. These organisations educate and empower women, advocate for the necessity of screening, and work to improve access to screening services.
Breast cancer screening test reimbursement policies and insurance coverage are thus, critical in driving market growth. Beneficial reimbursement policies make screening tests more accessible and inexpensive to patients, resulting in greater utilisation and demand.
Women are becoming more aware of the importance of breast health and regular screenings. Patients are increasingly taking an active role in their own health management, including seeking screening tests. These factors produces an opportune environment for the expansion of the breast cancer screening tests market.
Owed to the above factors, the global market is projected to grow at CAGR of 7.8% in forecasted period.
Breast cancer is one of the most common cancers among women around the world.
Early diagnosis using screening tests is critical for improving treatment outcomes and lowering mortality rates. As a result of the rising incidence and prevalence of breast cancer, the demand for screening tests is increasing.
Worldwide initiatives and awareness campaigns to encourage breast cancer screening have been established by governments and healthcare organizations.
These programs seek to inform the public about the value of early detection and motivate women to have routine screenings. Increased screening rates are a result of government funding and awareness programs, which further fuel the market.
Genetic testing for breast cancer susceptibility, such as BRCA gene testing, has gained prominence. Advances in genetic testing technologies and increased understanding of the genetic factors contributing to breast cancer risk have expanded the scope of screening. Genetic testing drives the adoption of personalized screening approaches and fuels market growth.
Breast cancer screening procedures, particularly mammography, can occasionally produce false-positive results, necessitating extra testing, biopsies, and concern for patients. Over diagnosis, or the detection and treatment of tumours that may or may not have caused harm, is also a source of worry. False positives and over diagnosis can increase healthcare expenses and endanger patients.
The most commonly used screening technique, mammography, may have limits in detecting breast cancer in individuals with dense breast tissue. Dense breasts have more fibrous and glandular tissue, making it difficult to detect minor abnormalities. Because of this limitation, women with dense breasts may have missed or delayed diagnoses, necessitating the adoption of additional screening procedures.
The cost of breast cancer screening tests, particularly more advanced imaging methods like breast MRI and molecular breast imaging, can be prohibitively expensive for certain people. Screening test costs and availability can vary depending on healthcare systems, insurance coverage, and individual financial circumstances. High costs may deter people from getting recommended screenings.
The USA occupies 31.4% of market share in 2022 globally. The expansion of the breast cancer screening tests market in the United States is highly impacted by a variety of variables, including public awareness initiatives, government policies, and technological advancements.
The United States Preventive Services Task Force (USPSTF) announced new drafting guidelines for breast cancer screening in May 2023, which significantly reduced the age at which women should begin screening from 50 to 40 years old. The main advantage of screening is that it allows for earlier detection of breast cancer. Breast cancer is virtually 100 percent treatable when detected early.
The USPSTF emphasised the importance of greater research regarding screening inequalities across different racial groups in the United States, as well as the benefits of breast ultrasonography and MRI for women with thick breasts.
The goal of these initiatives is to promote regular breast cancer screening, improve early detection rates, and ultimately reduce breast cancer mortality rates.
China expenditure on breast cancer screening test in 2022 was USD 122.4 Million.
The growing middle-class population in China has largely contributed to the expansion of the breast cancer screening tests market. Breast cancer screening tests are anticipated to become more popular as more individuals obtain access to healthcare facilities.
More importantly, advances in medical technology and the availability of novel screening techniques have supported market expansion. Digital mammography, breast ultrasonography, and breast magnetic resonance imaging (MRI), for example, are becoming more popular in China for breast cancer screening and diagnosis.
In 2022, the Germany held a significant share in the global market and contributed around USD 132.3 Million. Breast cancer is a major public health concern worldwide, especially in Germany.
Breast cancer screening programmes are in existence in Germany, like in other industrialised nations, to diagnose breast cancer at an early stage. For example, in May 2023, ESMO Breast Cancer conference was held in Germany for breast cancer researchers and physicians with a focus on innovation and care. This campaign was primarily concerned with current advancements in innovative breast cancer diagnostics, biomarkers, and treatments.
These programs usually include mammography screening for women of specific ages.
By diagnostic test type, imaging tests held 54.3% market share in world in 2022.
Imaging tests are the most effective technique to detect breast cancer early, when it is easier to treat and before it has grown large enough to produce symptoms. Regular imaging tests, such as mammograms, can help to reduce the chance of dying from breast cancer. A mammography is currently the most extensively used tool for detecting breast cancer in most women of screening age. These considerations are increasing the use of imaging testing.
The hospitals have a considerable presence in the breast cancer screening tests market, accounting for 42.3% value share in 2022, and exhibiting a high CAGR of 7.1% over the forecast period. The development of improved screening tests for cancer diagnosis and the rise in annual patient visits to hospitals around the world are both contributing factors to the rising usage of genetic testing.
Increasing government initiatives to equip hospitals with cutting-edge technology are some of the reasons that are fuelling the growth of this market.
Collaborations and partnerships among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten breast cancer screening test. Collaboration in research, development, and commercialization can lead to market expansion and the creation of new applications. Numerous large firms compete in the field of breast cancer screening test. Among the well-known players in this field are:
Similarly, recent developments related to the company’s manufacturing the breast cancer screening test kits have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Diagnostic Test, Type End, User and Region |
| Key Companies Profiled | AstraZeneca; Novartis; Sanofi; Pfizer; Bayer AG; GlaxoSmithKline plc; Siemens Healthineers; Hologic Inc.; General Electric Company; Koninklijke Philips NV; Fujifilm Holdings; A&G Pharmaceutical, Inc.; Biocrates Life Sciences AG; Metabolomic Technologies, Inc.; Myriad Genetics; OncoCyte Corporation; POC Medical Systems, Inc.; Hologic, Inc.; Provista Diagnostics, Inc.; BioTime, Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
Table 01: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Test Type
Table 02: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033 by End User
Table 03: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
Table 04: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 05: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Test Type
Table 06: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 07: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 08: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Test Type
Table 09: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 10: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 11: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Test Type
Table 12: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033by End User
Table 13: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 14: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Test Type
Table 15: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 16: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 17: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Test Type
Table 18: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 19: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 20: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Test Type
Table 21: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033by End User
Table 22: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 23: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Test Type
Table 24: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 by End User
Figure 01: Global Market Value (US$ Million) Analysis, 2017 to 2022
Figure 02: Global Market Forecast & Y-o-Y Growth, 2023 to 2033
Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2022–2033
Figure 04: Global Market Value Share (%) Analysis 2023 and 2033, by Diagnostic Test Type
Figure 05: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Diagnostic Test Type
Figure 06: Global Market Attractiveness Analysis 2023 to 2033, by Diagnostic Test Type
Figure 07: Global Market Value Share (%) Analysis 2023 and 2033, by End User
Figure 08: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by End User
Figure 09: Global Market Attractiveness Analysis 2023 to 2033, by End User
Figure 10: Global Market Value Share (%) Analysis 2023 and 2033, by Region
Figure 11: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Region
Figure 12: Global Market Attractiveness Analysis 2023 to 2033, by Region
Figure 13: North America Market Value (US$ Million) Analysis, 2017 to 2022
Figure 14: North America Market Value (US$ Million) Forecast, 2023 to 2033
Figure 15: North America Market Value Share, by Diagnostic Test Type (2023 E)
Figure 16: North America Market Value Share, by End User (2023 E)
Figure 17: North America Market Value Share, by Country (2023 E)
Figure 18: North America Market Attractiveness Analysis by Diagnostic Test Type, 2023 to 2033
Figure 19: North America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 20: U.S. Market Value Proportion Analysis, 2022
Figure 21: Global Vs. U.S. Growth Comparison
Figure 22: U.S. Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 23: U.S. Market Share Analysis (%) by End User, 2022 & 2033
Figure 24: Canada Market Value Proportion Analysis, 2022
Figure 25: Global Vs. Canada. Growth Comparison
Figure 26: Canada Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 27: Canada Market Share Analysis (%) by End User, 2022 & 2033
Figure 28: Latin America Market Value (US$ Million) Analysis, 2017 to 2022
Figure 29: Latin America Market Value (US$ Million) Forecast, 2023 to 2033
Figure 30: Latin America Market Value Share, by Diagnostic Test Type (2023 E)
Figure 31: Latin America Market Value Share, by End User (2023 E)
Figure 32: Latin America Market Value Share, by Country (2023 E)
Figure 33: Latin America Market Attractiveness Analysis by Diagnostic Test Type, 2023 to 2033
Figure 34: Latin America Market Attractiveness Analysis by End User, 2023 to 2033
Figure 35: Latin America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 36: Mexico Market Value Proportion Analysis, 2022
Figure 37: Global Vs Mexico Growth Comparison
Figure 38: Mexico Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 39: Mexico Market Share Analysis (%) by End User, 2022 & 2033
Figure 40: Brazil Market Value Proportion Analysis, 2022
Figure 41: Global Vs. Brazil. Growth Comparison
Figure 42: Brazil Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 43: Brazil Market Share Analysis (%) by End User, 2022 & 2033
Figure 44: Argentina Market Value Proportion Analysis, 2022
Figure 45: Global Vs Argentina Growth Comparison
Figure 46: Argentina Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 47: Argentina Market Share Analysis (%) by End User, 2022 & 2033
Figure 48: Europe Market Value (US$ Million) Analysis, 2017 to 2022
Figure 49: Europe Market Value (US$ Million) Forecast, 2023 to 2033
Figure 50: Europe Market Value Share, by Diagnostic Test Type (2023 E)
Figure 51: Europe Market Value Share, by End User (2023 E)
Figure 52: Europe Market Value Share, by Country (2023 E)
Figure 53: Europe Market Attractiveness Analysis by Diagnostic Test Type, 2023 to 2033
Figure 54: Europe Market Attractiveness Analysis by End User, 2023 to 2033
Figure 55: Europe Market Attractiveness Analysis by Country, 2023 to 2033
Figure 56: UK Market Value Proportion Analysis, 2022
Figure 57: Global Vs. UK Growth Comparison
Figure 58: UK Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 59: UK Market Share Analysis (%) by End User, 2022 & 2033
Figure 60: Germany Market Value Proportion Analysis, 2022
Figure 61: Global Vs. Germany Growth Comparison
Figure 62: Germany Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 63: Germany Market Share Analysis (%) by End User, 2022 & 2033
Figure 64: Italy Market Value Proportion Analysis, 2022
Figure 65: Global Vs. Italy Growth Comparison
Figure 66: Italy Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 67: Italy Market Share Analysis (%) by End User, 2022 & 2033
Figure 68: France Market Value Proportion Analysis, 2022
Figure 69: Global Vs France Growth Comparison
Figure 70: France Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 71: France Market Share Analysis (%) by End User, 2022 & 2033
Figure 72: Spain Market Value Proportion Analysis, 2022
Figure 73: Global Vs Spain Growth Comparison
Figure 74: Spain Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 75: Spain Market Share Analysis (%) by End User, 2022 & 2033
Figure 76: Russia Market Value Proportion Analysis, 2022
Figure 77: Global Vs Russia Growth Comparison
Figure 78: Russia Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 79: Russia Market Share Analysis (%) by End User, 2022 & 2033
Figure 80: BENELUX Market Value Proportion Analysis, 2022
Figure 81: Global Vs BENELUX Growth Comparison
Figure 82: BENELUX Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 83: BENELUX Market Share Analysis (%) by End User, 2022 & 2033
Figure 84: East Asia Market Value (US$ Million) Analysis, 2017 to 2022
Figure 85: East Asia Market Value (US$ Million) Forecast, 2023 to 2033
Figure 86: East Asia Market Value Share, by Diagnostic Test Type (2023 E)
Figure 87: East Asia Market Value Share, by End User (2023 E)
Figure 88: East Asia Market Value Share, by Country (2023 E)
Figure 89: East Asia Market Attractiveness Analysis by Diagnostic Test Type, 2023 to 2033
Figure 90: East Asia Market Attractiveness Analysis by End User, 2023 to 2033
Figure 91: East Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 92: China Market Value Proportion Analysis, 2022
Figure 93: Global Vs. China Growth Comparison
Figure 94: China Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 95: China Market Share Analysis (%) by End User, 2022 & 2033
Figure 96: Japan Market Value Proportion Analysis, 2022
Figure 97: Global Vs. Japan Growth Comparison
Figure 98: Japan Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 99: Japan Market Share Analysis (%) by End User, 2022 & 2033
Figure 100: South Korea Market Value Proportion Analysis, 2022
Figure 101: Global Vs South Korea Growth Comparison
Figure 102: South Korea Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 103: South Korea Market Share Analysis (%) by End User, 2022 & 2033
Figure 104: South Asia Market Value (US$ Million) Analysis, 2017 to 2022
Figure 105: South Asia Market Value (US$ Million) Forecast, 2023 to 2033
Figure 106: South Asia Market Value Share, by Diagnostic Test Type (2023 E)
Figure 107: South Asia Market Value Share, by End User (2023 E)
Figure 108: South Asia Market Value Share, by Country (2023 E)
Figure 109: South Asia Market Attractiveness Analysis by Diagnostic Test Type, 2023 to 2033
Figure 110: South Asia Market Attractiveness Analysis by End User, 2023 to 2033
Figure 111: South Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 112: India Market Value Proportion Analysis, 2022
Figure 113: Global Vs. India Growth Comparison
Figure 114: India Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 115: India Market Share Analysis (%) by End User, 2022 & 2033
Figure 116: Indonesia Market Value Proportion Analysis, 2022
Figure 117: Global Vs. Indonesia Growth Comparison
Figure 118: Indonesia Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 119: Indonesia Market Share Analysis (%) by End User, 2022 & 2033
Figure 120: Malaysia Market Value Proportion Analysis, 2022
Figure 121: Global Vs. Malaysia Growth Comparison
Figure 122: Malaysia Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 123: Malaysia Market Share Analysis (%) by End User, 2022 & 2033
Figure 124: Thailand Market Value Proportion Analysis, 2022
Figure 125: Global Vs. Thailand Growth Comparison
Figure 126: Thailand Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 127: Thailand Market Share Analysis (%) by End User, 2022 & 2033
Figure 128: Oceania Market Value (US$ Million) Analysis, 2017 to 2022
Figure 129: Oceania Market Value (US$ Million) Forecast, 2023 to 2033
Figure 130: Oceania Market Value Share, by Diagnostic Test Type (2023 E)
Figure 131: Oceania Market Value Share, by End User (2023 E)
Figure 132: Oceania Market Value Share, by Country (2023 E)
Figure 133: Oceania Market Attractiveness Analysis by Diagnostic Test Type, 2023 to 2033
Figure 134: Oceania Market Attractiveness Analysis by End User, 2023 to 2033
Figure 135: Oceania Market Attractiveness Analysis by Country, 2023 to 2033
Figure 136: Australia Market Value Proportion Analysis, 2022
Figure 137: Global Vs. Australia Growth Comparison
Figure 138: Australia Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 139: Australia Market Share Analysis (%) by End User, 2022 & 2033
Figure 140: New Zealand Market Value Proportion Analysis, 2022
Figure 141: Global Vs New Zealand Growth Comparison
Figure 142: New Zealand Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 143: New Zealand Market Share Analysis (%) by End User, 2022 & 2033
Figure 144: Middle East & Africa Market Value (US$ Million) Analysis, 2017 to 2022
Figure 145: Middle East & Africa Market Value (US$ Million) Forecast, 2023 to 2033
Figure 146: Middle East & Africa Market Value Share, by Diagnostic Test Type (2023 E)
Figure 147: Middle East & Africa Market Value Share, by End User (2023 E)
Figure 148: Middle East & Africa Market Value Share, by Country (2023 E)
Figure 149: Middle East & Africa Market Attractiveness Analysis by Diagnostic Test Type, 2023 to 2033
Figure 150: Middle East & Africa Market Attractiveness Analysis by End User, 2023 to 2033
Figure 151: Middle East & Africa Market Attractiveness Analysis by Country, 2023 to 2033
Figure 152: GCC Countries Market Value Proportion Analysis, 2022
Figure 153: Global Vs GCC Countries Growth Comparison
Figure 154: GCC Countries Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 155: GCC Countries Market Share Analysis (%) by End User, 2022 & 2033
Figure 156: Türkiye Market Value Proportion Analysis, 2022
Figure 157: Global Vs. Türkiye Growth Comparison
Figure 158: Türkiye Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 159: Türkiye Market Share Analysis (%) by End User, 2022 & 2033
Figure 160: South Africa Market Value Proportion Analysis, 2022
Figure 161: Global Vs. South Africa Growth Comparison
Figure 162: South Africa Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 163: South Africa Market Share Analysis (%) by End User, 2022 & 2033
Figure 164: Northern Africa Market Value Proportion Analysis, 2022
Figure 165: Global Vs Northern Africa Growth Comparison
Figure 166: Northern Africa Market Share Analysis (%) by Diagnostic Test Type, 2022 & 2033
Figure 167: Northern Africa Market Share Analysis (%) by End User, 2022 & 2033
The market is valued at USD 2.1 billion in 2023.
GE Healthcare, Siemens Healthineers, Fujifilm Holdings Corporation, and Hologic Inc. are key breast cancer screening test market players.
Mammography is the key segment by product type and is likely to remain preferred through 2033.
Players opt for product launches, partnerships, and mergers and acquisitions.
China, India, and Japan dominate the Asian market.
Explore Similar Insights
Breast Cancer Screening Tests Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
